Photo:
patrick t. fallon/Agence France-Presse/Getty Images
The latest Market Talks covering the Health Care sector. Published exclusively on Dow Jones Newswires at 4:20 ET, 12:20 ET and 16:50 ET.
0804 GMT –
’ appointment
Riad Mishlawi
CEO is in line with analysts’ preference for the role, Citi analyst Peter Verdult says in a note. This was due to his track record at the injectables division—he is its current head—since 1990, his understanding of the company’s culture and ease with capital markets, Verdult says. The board has charged Riad with executing on the five-year plan and potentially using its strong balance sheet to develop new strategic opportunities, Verdult says. “Year-to-date business trends…are encouraging putting Hikma well on track to deliver on guidance, with risks to the upside in our view,” he says. Citi rates the stock buy with a 1,920-pence target price. (anthony.orunagoriainoff@dowjones.com)
0801 GMT –
is poised to be a key beneficiary of a social-security scheme change in Thailand thanks to the large proportion of patients it gets via the program, CGS-CIMB analyst Kasem Prunratanamala says in a report. The Social Security Office is set to raise its “capitation” rate—a rate on fixed payments that workers make each year—by 10% from May 1, a move that should benefit the hospital as it has the most exposure to social-security scheme patients of all private hospitals in Thailand, the analyst says. The brokerage expects the change to boost Bangkok Chain Hospital’s net profit by 5% for 2023, and by 6% for 2024. CGS-CIMB raises the stock’s target to THB22.00 from THB21.20 and maintains a hold rating. (ronnie.harui@wsj.com)
0334 GMT –
is set to benefit from its dietary supplement ProGsterol,
…
Click Here to Read the Full Original Article at WSJ.com: World News…